USPTO to increase IPR fees by 33% and PGR fees by 27% in 2018
Contributed by Knobbe Martens. Originally published on Patexia; republished here as part of the LexDana archive.
The USPTO announced that the official fees for IPR and PGR will increase significantly starting on January 16, 2018. See 82 Fed. Reg. 52780, 52807 (Nov. 14, 2017).
The IPR petition request fee will increase $6,500 (from $9,000 to $15,500) and the post-institution fee will increase $1,000 (from $14,000 to $15,000) for a total increase in combined fees of $7,500 (from $23,000 to $30,500). The new combined fees represent a 33% increase over the old combined fees. In addition, the request fee for each claim in excess of 20 will increase $100 (from $200 to $300). The post-institution fee for each claim in excess of 15 will increase $200 (from $400 to $600).
The PGR petition request fee will increase $4,000 (from $12,000 to $16,000) and the post-institution fee will increase $4,000 (from $18,000 to $22,000) for a total increase in combined fees of $8,000 (from $30,000 to $38,000). The new combined fees represent a 27% increase over the old combined fees. In addition, the request fee for each claim in excess of 20 will increase $125 (from $250 to $375). The post-institution fee for each claim in excess of 15 will increase $275 (from $550 to $825).
The table of fee changes is provided below:
Parties considering filing IPR and PGR petitions may want to get their petitions on file before January 16, 2018 to take advantage of the current fees.
Written By: Nathanael R. Luman, Ph.D. and Kerry S. Taylor, Ph.D.
More insights
Fresh From the Bench: Latest Precedential Patent Case
Ridge Corp. et al. v. Kirk NationaLease Co. et al. , Appeal No. 2025-1254 (Fed. Cir. July 13, 2026) In its only precedential patent opinion last week, the Federal Circuit considered an appeal of a preliminary injunction issued by the U.S. District Court…
Fresh From the Bench: Latest Precedential Patent Cases
CASE OF THE WEEK Wyeth LLC v. AstraZeneca Pharmaceuticals LP , Appeal No. 2024-2325 (Fed. Cir. July 9, 2026) In our Case of the Week, the Federal Circuit affirmed a district court ruling reversing a $107.5 million jury verdict against AstraZeneca in a case…
Enanta Pharmaceuticals, Inc. v. Pfizer Inc., Appeal No. 2025-1427 (Fed. Cir. Jun. 23, 2026)
CASE OF THE WEEK Enanta Pharmaceuticals, Inc. v. Pfizer Inc., Appeal No. 2025-1427 (Fed. Cir. Jun. 23, 2026) In our Case of the Week, the Federal Circuit affirmed summary judgment invalidating all claims of Enanta’s Patent No. 11,358,953 as…